Patent · US Active

Compounds and uses thereof to induce an immunogenic cancer cell death in a subject

US8828944B2 · kind B2 · utility

1Cited by
2References
2Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 1, 2011
Grant dateSep 9, 2014
Priority date
Expiry dateApr 1, 2031

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12Q2600/172
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumor. These methods comprise a step of determining the ability of the treatment, of the subject and/or of the tumor to induce an anticancer immune response, the inability of at least one of the treatment, the subject and the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the therapeutic treatment of cancer. Inventors in particular identify genes specific of a human subject or of cancerous cells which can be used to predict or assess the sensitivity of a subject to a treatment of cancer. The invention also relates to particular compounds capable of activating or enhancing the immune system of a particular subject, when the subject is exposed to a therapeutic treatment of cancer or before such an exposition. It further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The p…

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.